Lack of association between serum transforming growth factor-beta 1 and cancer mortality risk in a nested case-control study in Japan.
We examined the potential role of serum TGF-beta 1 levels to predict cancer mortality risk in a nested case-control study within a large prospective cohort of middle-aged and elderly Japanese subjects. The cases were 893 persons who provided blood samples at baseline and subsequently died of cancer from all sites during the follow-up period. A total of 2,824 subjects were selected from the main study as controls, matched with the cases for sex, age and study area. Serum TGF-beta 1 levels were measured using a quantitative sandwich enzyme immunoassay. The odds ratios and 95% confidence intervals for each quartile were calculated using a conditional logistic regression model. Mean serum TGF-beta 1 levels were approximately 36 ng/ml in both cases and controls, with no significant difference . Overall, serum TGF-beta 1 levels were not associated with total cancer mortality after adjustment for potential confounding factors like age, body mass index or cigarette smoking. Serum TGF-beta 1 levels may thus not be associated with cancer mortality risk in apparently health individuals.